149 related articles for article (PubMed ID: 25083424)
21. Diagnostic value of HBME-1, CK19, Galectin 3, and CD56 in the subtypes of follicular variant of papillary thyroid carcinoma.
Cho H; Kim JY; Oh YL
Pathol Int; 2018 Nov; 68(11):605-613. PubMed ID: 30350394
[TBL] [Abstract][Full Text] [Related]
22. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
[TBL] [Abstract][Full Text] [Related]
23. CD56, CD57, HBME1, CK19, Galectin-3 and p63 immunohistochemical stains in differentiating diagnosis of thyroid benign/malign lesions and NIFTP.
Tastekin E; Keskin E; Can N; Canberk S; Mut A; Erdogan E; Asa N; Güldiken S; Sezer A; Azatcam M
Pol J Pathol; 2019; 70(4):286-294. PubMed ID: 32146798
[TBL] [Abstract][Full Text] [Related]
24. Expression of cytokeratin-19 (CK19) in the classical subtype of papillary thyroid carcinoma: the experience of one center in the Silesian region.
Kaliszewski K; Diakowska D; Strutynska-Karpinska M; Rzeszutko M; Grzegrzolka J; Dziegiel P; Wojtczak B; Sutkowski K
Folia Histochem Cytobiol; 2016; 54(4):193-201. PubMed ID: 28051274
[TBL] [Abstract][Full Text] [Related]
25. [Expression and significance of VEGF, VEGF-C, and VEGF-D in papillary thyroid carcinoma].
Jiang HG; Gao M; Tang WP; Li FH; Cai QZ
Ai Zheng; 2005 Sep; 24(9):1136-9. PubMed ID: 16159441
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
Rossi ED; Raffaelli M; Mule' A; Miraglia A; Lombardi CP; Vecchio FM; Fadda G
Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
[TBL] [Abstract][Full Text] [Related]
28. HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma.
Nga ME; Lim GS; Soh CH; Kumarasinghe MP
Diagn Cytopathol; 2008 Aug; 36(8):550-6. PubMed ID: 18618720
[TBL] [Abstract][Full Text] [Related]
29. Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis.
Ma H; Yan J; Zhang C; Qin S; Qin L; Liu L; Wang X; Li N
Int J Clin Exp Pathol; 2014; 7(11):7999-8007. PubMed ID: 25550843
[TBL] [Abstract][Full Text] [Related]
30. [Expression of VEGF-C and angiogenesis, and lymphangiogenesis in papillary thyroid carcinoma].
Liang QC; Wei QY; Fan SQ
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Jun; 31(3):414-6, 419. PubMed ID: 16859137
[TBL] [Abstract][Full Text] [Related]
31. [Detection of galectin-3 in both serum and tissue for early diagnosis of thyroid carcinoma].
Xue G; Liu J; Huang J; Zhang J; Zhang W; Wu J; Shang X
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jul; 33(7):1027-30. PubMed ID: 23895846
[TBL] [Abstract][Full Text] [Related]
32. Differential expression of galectin-3 in papillary projections of malignant and non-malignant hyperplastic thyroid lesions.
Cvejić D; Savin S; Petrović I; Paunović I; Tatić S; Havelka M
Acta Chir Iugosl; 2003; 50(3):67-70. PubMed ID: 15179758
[TBL] [Abstract][Full Text] [Related]
33. Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma.
Salajegheh A; Pakneshan S; Rahman A; Dolan-Evans E; Zhang S; Kwong E; Gopalan V; Lo CY; Smith RA; Lam AK
Hum Pathol; 2013 Oct; 44(10):2204-12. PubMed ID: 23845470
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid.
Erkiliç S; Aydin A; Koçer NE
Endocr Pathol; 2002; 13(3):207-11. PubMed ID: 12446919
[TBL] [Abstract][Full Text] [Related]
35. [Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis].
He CN; He L; Cheng JQ; Chen SC; Zhao HF; Zhai JP; Zhang J
Zhonghua Bing Li Xue Za Zhi; 2008 Jan; 37(1):35-9. PubMed ID: 18509983
[TBL] [Abstract][Full Text] [Related]
36. Concordance study between one-step nucleic acid amplification and morphologic techniques to detect lymph node metastasis in papillary carcinoma of the thyroid.
del Carmen S; Gatius S; Franch-Arcas G; Baena JA; Gonzalez O; Zafon C; Cuevas D; Valls J; Pérez A; Martinez M; Ros S; Macías CG; Iglesias C; Matías-Guiu X; de Álava E
Hum Pathol; 2016 Feb; 48():132-41. PubMed ID: 26614398
[TBL] [Abstract][Full Text] [Related]
37. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
[TBL] [Abstract][Full Text] [Related]
38. Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: improvement in the sensitivity or specificity?
Wu G; Wang J; Zhou Z; Li T; Tang F
J Int Med Res; 2013 Aug; 41(4):975-83. PubMed ID: 23857157
[TBL] [Abstract][Full Text] [Related]
39. Extremely Well-Differentiated Papillary Thyroid Carcinoma Resembling Adenomatous Hyperplasia Can Metastasize to the Skull: A Case Report.
Pyo JY; Kim J; Choi SE; Shin E; Yang SW; Park CS; Kim SM; Hong S
Yonsei Med J; 2017 Jan; 58(1):255-258. PubMed ID: 27873522
[TBL] [Abstract][Full Text] [Related]
40. Galectin-1 is a diagnostic marker involved in thyroid cancer progression.
Arcolia V; Journe F; Wattier A; Leteurtre E; Renaud F; Gabius HJ; Remmelink M; Decaestecker C; Rodriguez A; Boutry S; Laurent S; Saussez S
Int J Oncol; 2017 Sep; 51(3):760-770. PubMed ID: 28677745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
